A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression.
about
Ketamine and other glutamate receptor modulators for depression in adultsTreatment-Resistant Major Depression: Rationale for NMDA Receptors as Targets and Nitrous Oxide as TherapyD-Cycloserine in Neuropsychiatric Diseases: A Systematic ReviewChallenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved TherapeuticsGLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonistsA brief history of the development of antidepressant drugs: from monoamines to glutamateEssential role of GluD1 in dendritic spine development and GluN2B to GluN2A NMDAR subunit switch in the cortex and hippocampus reveals ability of GluN2B inhibition in correcting hyperconnectivity.The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition.1-aminocyclopropanecarboxylic acid (ACPC) produces procognitive but not antipsychotic-like effects in rats.Rapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: Characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats.Glutamate and its receptors in the pathophysiology and treatment of major depressive disorderCombining d-cycloserine with motor training does not result in improved general motor learning in neurologically intact people or in people with stroke.Inflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders.Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain.Glutamate NMDA receptor modulators for the treatment of depression: trials and tribulations.Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.Beyond serotonin: newer antidepressants in the future.Biomarkers for Psychiatry: The Journey from Fantasy to Fact, a Report of the 2013 CINP Think TankNovel Glutamatergic Treatments for Severe Mood Disorders.Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond.ON or OFF?: Modulating the N-Methyl-D-Aspartate Receptor in Major Depression.Therapeutic Modulation of Glutamate Receptors in Major Depressive DisorderTowards the Molecular Foundations of Glutamatergic-targeted Antidepressants.Novel glutamatergic drugs for the treatment of mood disorders.NMDA antagonists under investigation for the treatment of major depressive disorder.A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?Issues encountered in recent attempts to develop novel antidepressant agents.Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry.New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity.Targeting glutamate signalling in depression: progress and prospects.Glutamate-Based Drug Discovery for Novel Antidepressants.Mood Therapeutics: Novel Pharmacological Approaches for Treating DepressionAdministration of ketamine for unipolar and bipolar depression.Synergistic antidepressant-like effect of the joint administration of caffeine and NMDA receptor ligands in the forced swim test in mice.Molecular mechanisms of D-cycloserine in facilitating fear extinction: insights from RNAseq.Therapeutic implications for NMDA receptors in mood disorders.Increased serum levels of serine enantiomers in patients with depression.
P2860
Q24186746-AB78698D-61E0-4789-B8F2-408A2D05C1FAQ26773084-92DA2ADC-75A6-4C23-B370-97F15A9789A7Q26781321-18732F1D-2431-42F2-84E4-94A77345B998Q26782997-6EEAD466-44FB-499E-AE9E-6937F7E79412Q27025974-33EC3206-B717-4E18-8F47-ED7034D7EF11Q27028050-52E45EBD-6497-43C8-A9B8-FA8AC0580F04Q27305133-A523CDFE-0107-4594-ACFD-F3AA6D5C99E3Q30373328-E5BFDB24-7D09-4F6B-B7DE-70DCC18BFCA4Q30418172-790E0EE8-9691-4D7F-A607-B642D3C89893Q30695515-58E6B2F9-1BF8-4EEE-A520-8432F158BDF8Q30711088-87C54BE4-9963-4A8B-8924-1AD116755D28Q33708292-EE8969DD-EE9B-4B9D-A129-2ADAC993061BQ33721019-C3825B55-16C3-4485-9801-607CE350D6B9Q34381226-7E78A370-727B-4F6B-8469-AA9CA16D4722Q34466310-1B9563E0-7941-4C51-A5FA-9498CB35C26BQ34475595-151CDD19-A0DE-4D2F-A41B-AE114963F8E8Q34512818-D7E1954D-9DD7-4070-ABB6-5A3C5F8FC21DQ34551188-0F24286F-21B3-40BA-A13F-E416CE9B474DQ34557706-5BA28309-6478-41DA-AC62-5A3FC069407DQ36287896-BD8D4A05-91BD-4728-B5BB-E2DC50491E62Q36498659-ED2D4F37-6606-49FF-80C9-D9E1CDE6AD88Q36899381-78890FC7-5C31-4A9D-B89B-735C4B0374F0Q37583961-96CB9838-0263-49E2-835D-3915277B7338Q37668014-39F809EB-7704-4906-88D4-302BD9274216Q37668029-5DBE290E-593A-4051-9D38-F9949B8C9450Q38131480-75270629-D6FA-4DCE-AC37-B64D4FBDF18BQ38211107-F52CD535-9C6E-41A9-B4A8-2A87462C3F76Q38227967-0D5B2036-0212-4F68-BA6A-03E24E57815FQ38254452-6851412B-BFDE-4E9D-84AA-85AB3298BA4FQ38374429-2E6708D9-F00E-46D0-886A-9953DF8DEEBFQ38626082-9C0E451B-6CA5-460D-8E55-9B7978A1CF2DQ38685420-5BDC8106-EF0A-4F34-9B5E-BF40C801E5FDQ38743867-C51C830C-64EB-4C77-BE96-F0D5C4D4C722Q38895017-9AD5B8F3-75AD-417B-8004-118ED86AF920Q38990885-3260D5E0-5E60-4980-BDCD-F82611D7E13CQ39093325-BC7888FA-B9A2-4F63-9515-3F3699789549Q39430303-72491FE2-ECA3-40C2-8CFC-1861700CC1DEQ40508281-9AE51CE9-DF7F-4878-8FC1-7D7F25044D51Q47901451-DA74E996-03CD-4493-8D3C-B93A5584FC5FQ48071667-4C2C3E2F-CBE7-4397-8D57-06CE6B45E240
P2860
A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression.
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression.
@ast
A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression.
@en
A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression.
@nl
type
label
A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression.
@ast
A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression.
@en
A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression.
@nl
prefLabel
A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression.
@ast
A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression.
@en
A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression.
@nl
P2093
P2860
P1476
A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression.
@en
P2093
Boaz Bloch
Genia Gelfin
Ilana Kremer
Shani Edelman
Uriel Heresco-Levy
P2860
P304
P356
10.1017/S1461145712000910
P577
2012-09-17T00:00:00Z